CA2266346A1 - Utilisation de proteines comme agents actifs contre des maladies auto-immunes - Google Patents

Utilisation de proteines comme agents actifs contre des maladies auto-immunes Download PDF

Info

Publication number
CA2266346A1
CA2266346A1 CA002266346A CA2266346A CA2266346A1 CA 2266346 A1 CA2266346 A1 CA 2266346A1 CA 002266346 A CA002266346 A CA 002266346A CA 2266346 A CA2266346 A CA 2266346A CA 2266346 A1 CA2266346 A1 CA 2266346A1
Authority
CA
Canada
Prior art keywords
ala
val
gly
ser
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002266346A
Other languages
English (en)
Inventor
Alberto E. Panerai
Alberto Bartorelli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zetesis SpA
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from ITMI961919 external-priority patent/IT1284553B1/it
Priority claimed from ITMI961921 external-priority patent/IT1284555B1/it
Priority claimed from ITMI961920 external-priority patent/IT1284554B1/it
Priority claimed from ITMI961922 external-priority patent/IT1284556B1/it
Application filed by Individual filed Critical Individual
Publication of CA2266346A1 publication Critical patent/CA2266346A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/843—Digestive system
    • Y10S530/846—Liver

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne l'utilisation de protéines extraites d'organes d'animaux à l'aide d'acide perchlorique. Lesdites protéines sont utilisées dans la préparation de médicaments actifs contre des maladies auto-immunes, et en particulier contre l'athérosclérose, l'arthrite, la sclérose en plaque, le diabète.
CA002266346A 1996-09-18 1997-09-17 Utilisation de proteines comme agents actifs contre des maladies auto-immunes Abandoned CA2266346A1 (fr)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
ITMI96A001921 1996-09-18
ITMI961919 IT1284553B1 (it) 1996-09-18 1996-09-18 Uso di proteine come agenti antiartritici
ITMI961921 IT1284555B1 (it) 1996-09-18 1996-09-18 Uso di proteine come agenti antidiabetici
ITMI96A001922 1996-09-18
ITMI96A001920 1996-09-18
ITMI96A001919 1996-09-18
ITMI961920 IT1284554B1 (it) 1996-09-18 1996-09-18 Uso di proteine come agenti antiaterosclerotici
ITMI961922 IT1284556B1 (it) 1996-09-18 1996-09-18 Uso di proteine come agenti contro la sclerosi multipla
PCT/EP1997/005079 WO1998011909A1 (fr) 1996-09-18 1997-09-17 Utilisation de proteines comme agents actifs contre des maladies auto-immunes

Publications (1)

Publication Number Publication Date
CA2266346A1 true CA2266346A1 (fr) 1998-03-26

Family

ID=27453037

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002266346A Abandoned CA2266346A1 (fr) 1996-09-18 1997-09-17 Utilisation de proteines comme agents actifs contre des maladies auto-immunes

Country Status (22)

Country Link
US (2) US6468536B1 (fr)
EP (1) EP0928197B1 (fr)
JP (1) JP2001501925A (fr)
KR (1) KR20000036207A (fr)
CN (1) CN1151838C (fr)
AR (1) AR009952A1 (fr)
AT (1) ATE233569T1 (fr)
AU (1) AU723669B2 (fr)
BR (1) BR9711499A (fr)
CA (1) CA2266346A1 (fr)
CZ (1) CZ293926B6 (fr)
DE (1) DE69719525T2 (fr)
DK (1) DK0928197T3 (fr)
ES (1) ES2192669T3 (fr)
IL (1) IL129024A0 (fr)
NO (1) NO991175D0 (fr)
NZ (1) NZ334714A (fr)
PL (1) PL188746B1 (fr)
PT (1) PT928197E (fr)
RU (1) RU2196606C2 (fr)
TR (1) TR199900596T2 (fr)
WO (1) WO1998011909A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7112655B1 (en) 1997-02-27 2006-09-26 Japan Tobacco, Inc. JTT-1 protein and methods of inhibiting lymphocyte activation
JP3521382B2 (ja) 1997-02-27 2004-04-19 日本たばこ産業株式会社 細胞間接着及びシグナル伝達を媒介する細胞表面分子
IT1290828B1 (it) * 1997-03-25 1998-12-11 Zetesis Spa Uso di proteine estraibili da organi animali per la preparazione di medicamenti per il trattamento di condizioni patologiche
JP4210454B2 (ja) 2001-03-27 2009-01-21 日本たばこ産業株式会社 炎症性腸疾患治療剤
JP3871503B2 (ja) 1999-08-30 2007-01-24 日本たばこ産業株式会社 免疫性疾患治療剤
JP3597140B2 (ja) 2000-05-18 2004-12-02 日本たばこ産業株式会社 副刺激伝達分子ａｉｌｉｍに対するヒトモノクローナル抗体及びその医薬用途
US6855694B2 (en) * 2000-06-08 2005-02-15 Rakepoll Holding B.V. Method of treatment of amyotrophic lateral sclerosis with a protein extractable from mammalian organs
JP4212278B2 (ja) 2001-03-01 2009-01-21 日本たばこ産業株式会社 移植片拒絶反応抑制剤
ITMI20010762A1 (it) * 2001-04-10 2002-10-10 Zetesis Spa Uso della proteina uk114 o di suoi frammenti per il trattamento e la prevenzione dello shock endotossico
ITMI20010761A1 (it) * 2001-04-10 2002-10-10 Zetesis Spa Uso della proteina uk114 per il trattamento e la prevenzione dell'epatite cronica attiva
US20070275890A1 (en) * 2004-01-16 2007-11-29 Johnson Barbara J Chaperonin 10 Modulation Of Toll-Like Receptor-Inducible Cytokine And Chemokine Secretion

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4024247A (en) 1971-12-27 1977-05-17 Palolab Pharmaceuticals Corporation Composition and method of using a protein mixture derived from liver
IT1244879B (it) 1990-12-11 1994-09-12 Alberto Bartorelli Estratti da tessuti animali, utili in terapia e in diagnostica.
FR2688227A1 (fr) * 1992-03-04 1993-09-10 Inst Nat Sante Rech Med Proteines formant des complexes avec des chaperones et leurs ligands, leurs fragments, leur obtention et leurs applications biologiques.
IT1270618B (it) * 1994-07-14 1997-05-07 Zetesis Spa Proteine ad attivita' antitumorale

Also Published As

Publication number Publication date
CZ293926B6 (cs) 2004-08-18
AU4774797A (en) 1998-04-14
PL188746B1 (pl) 2005-04-29
DE69719525T2 (de) 2003-10-02
ATE233569T1 (de) 2003-03-15
PL332282A1 (en) 1999-08-30
TR199900596T2 (xx) 1999-06-21
CN1230892A (zh) 1999-10-06
NO991175L (no) 1999-03-10
KR20000036207A (ko) 2000-06-26
NO991175D0 (no) 1999-03-10
BR9711499A (pt) 1999-08-24
DK0928197T3 (da) 2003-06-23
CZ91599A3 (cs) 1999-08-11
WO1998011909A1 (fr) 1998-03-26
US20030108558A1 (en) 2003-06-12
EP0928197A1 (fr) 1999-07-14
CN1151838C (zh) 2004-06-02
NZ334714A (en) 2000-08-25
PT928197E (pt) 2003-06-30
RU2196606C2 (ru) 2003-01-20
AR009952A1 (es) 2000-05-17
EP0928197B1 (fr) 2003-03-05
ES2192669T3 (es) 2003-10-16
JP2001501925A (ja) 2001-02-13
DE69719525D1 (de) 2003-04-10
IL129024A0 (en) 2000-02-17
AU723669B2 (en) 2000-08-31
US6468536B1 (en) 2002-10-22

Similar Documents

Publication Publication Date Title
EP1776958B1 (fr) Inhibiteurs peptidiques à permeabilité cellulaire, du mecanisme de transduction du signal de JNK
KR100509438B1 (ko) 경구적으로 활성인 여주의 분획, 이것의 활성 펩티드 및 당뇨병 치료에 있어서 이들의 사용
US7745588B2 (en) Antibodies to a paralytic peptide
JPH09510715A (ja) 摂食抑制ペプチド
AU723669B2 (en) Use of proteins as agents against autoimmune diseases
KR20110119707A (ko) 비만 치료
CA2082804A1 (fr) Methodes et compositions pour le traitement des affections angiogeniques
FI120308B (fi) Peptidi, joka pystyy neutraloimaan tai muuntamaan myeliinin emäksisen proteiinin vasta-aineen tuoton
US5776758A (en) Cysteine protease derived from parasitic helminths
US3864481A (en) Anti disease producing synthetic material for the prevention suppression and diagnosis of multiple sclerosis and method of treatment therefor
CA3059094A1 (fr) Composes a base de c4bp pour le traitement de maladies immunologiques
KR950702579A (ko) 트롬빈 억제제(thrombin inhibitors)
AU2014239186B2 (en) Apolipoprotein mimetics and uses thereof
EP0969859A1 (fr) Utilisation de proteines extraites d'organes d'animaux pour la preparation de medicaments pour traiter les pathologies caracterisees par une hyperproduction de facteur de necrose des tumeurs (tnf)
US20040136978A1 (en) Abin-mediated hepatitis protection
MXPA99002571A (en) Use of proteins as agents against autoimmune diseases
KR101019246B1 (ko) 역순 광학 이성체 펩티드를 포함하는 약제학적 조성물
MXPA99008721A (en) The use of proteins extractable from animal organs for the preparation of medicaments for the treatment of pathological conditions characterized by hyperproduction of tumor necrosis factor (tnf)
MXPA01012663A (es) Uso de interleucina-11 para tratar el shock hemorragico.
JPH0680695A (ja) ペプチド
KR20160040553A (ko) 다발성 경화증 치료 및 예방용 조성물
CA2443726A1 (fr) Utilisation de proteine uk114 ou de fragments de celle-ci pour le traitement et la prevention de choc endotoxique

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued